Perspective Therapeutics (CATX) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Perspective Therapeutics (CATX) over the last 16 years, with Q2 2025 value amounting to $514000.0.

  • Perspective Therapeutics' Net Income towards Common Stockholders rose 20489.8% to $514000.0 in Q2 2025 from the same period last year, while for Sep 2025 it was $514000.0, marking a year-over-year increase of 10838.23%. This contributed to the annual value of -$949000.0 for FY2024, which is 8951.73% up from last year.
  • According to the latest figures from Q2 2025, Perspective Therapeutics' Net Income towards Common Stockholders is $514000.0, which was up 20489.8% from -$490000.0 recorded in Q2 2024.
  • In the past 5 years, Perspective Therapeutics' Net Income towards Common Stockholders registered a high of $514000.0 during Q2 2025, and its lowest value of -$5.2 million during Q4 2023.
  • In the last 5 years, Perspective Therapeutics' Net Income towards Common Stockholders had a median value of -$1.5 million in 2023 and averaged -$1.7 million.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first crashed by 21326.82% in 2021, then skyrocketed by 20489.8% in 2025.
  • Over the past 5 years, Perspective Therapeutics' Net Income towards Common Stockholders (Quarter) stood at -$1.6 million in 2021, then plummeted by 41.83% to -$2.3 million in 2022, then plummeted by 127.82% to -$5.2 million in 2023, then soared by 90.55% to -$490000.0 in 2024, then soared by 204.9% to $514000.0 in 2025.
  • Its last three reported values are $514000.0 in Q2 2025, -$490000.0 for Q2 2024, and -$459000.0 during Q1 2024.